Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: adalimumab 40 mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)

NCT01870986
View directory record Official record
Conditions
Healthy
Interventions
PF-06410293, Humira (adalimumab-EU), Humira (adalimumab-US)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Results available

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

NCT01119859
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Adalimumab, Placebo to tocilizumab, Placebo to adalimumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT00408629
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
adalimumab, placebo
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
36
States / cities
Anaheim, California • Wheat Ridge, Colorado • Hamden, Connecticut + 29 more
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

NCT02889796
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
48
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 21, 2026, 5:48 AM EDT
Recruiting Phase 3 Interventional

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

NCT06654882
View directory record Official record
Conditions
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions
TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib
Drug
Lead sponsor
Duke University
Other
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Results available

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

NCT01185288
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
46
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Results available

Treatments Against RA and Effect on FDG-PET/CT

NCT02374021
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 21, 2026, 5:48 AM EDT
Recruiting No phase listed Observational

CHronic Nonbacterial Osteomyelitis International Registry

NCT04725422
View directory record Official record
Conditions
Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
Interventions
Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

NCT01712178
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, current formulation, Adalimumab, new formulation
Biological
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Mesa, Arizona • Hemet, California • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

NCT00195663
View directory record Official record
Conditions
Early Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

NCT03104400
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
114
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

NCT02497469
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab, Adalimumab placebo, Adalimumab, Vedolizumab placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

NCT02808975
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Placebo, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Beverly Hills, California • Encino, California • Irvine, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

NCT02745080
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab, Adalimumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
853 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
19
States / cities
Fountain Valley, California • Fullerton, California • La Mesa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

MAP Study: Methotrexate and Adalimumab in Psoriasis

NCT03217734
View directory record Official record
Conditions
Psoriasis
Interventions
Adalimumab, Methotrexate, Placebo
Biological · Drug
Lead sponsor
Jeffrey J Crowley MD
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Bakersfield, California • Santa Monica, California • Rockville, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

NCT00566722
View directory record Official record
Conditions
Psoriasis
Interventions
adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Sep 21, 2026, 5:48 AM EDT
Recruiting Phase 2 Interventional

Effects of TNF Blockade on Human BPH/LUTS

NCT06062875
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Adalimumab
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 21, 2026, 5:48 AM EDT
Recruiting Phase 4 Interventional

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

NCT06045754
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab, Adalimumab, Ustekinumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
41
States / cities
Dothan, Alabama • Sun City, Arizona • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Results available

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

NCT02814175
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
methotrexate (MTX), adalimumab (ADA)
Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Sun City, Arizona • Miami, Florida • Vernon Hills, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 21, 2026, 5:48 AM EDT
Completed No phase listed Observational

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

NCT02330380
View directory record Official record
Conditions
Psoriasis, Inflammation
Interventions
Methotrexate, Ustekinumab, Etanercept, Adalimumab, Acitretin, UVB Excimer Laser, Narrowband UVB
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

NCT00348283
View directory record Official record
Conditions
Crohn's Disease
Interventions
adalimumab, placebo
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2011 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Study of Adalimumab in Patients With Axial Spondyloarthritis

NCT00939003
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Adalimumab, Placebo, Open-label Adalimumab
Biological
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 21, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Remission in Subjects With Crohn's Disease, Open Label Extension

NCT01070303
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab 40 mg eow or ew
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
43
States / cities
Berkeley, California • Long Beach, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2011 · Synced Sep 21, 2026, 5:48 AM EDT